Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.

Pharmacogenetics - 1 Apr 1997

Sabbagh N, Delaporte E, Marez D, Lo-Guidice J M, Piette F, Broly F

Abstract excerpt

Sulfasalazine is an effective agent for chronic discoid lupus erythematosus (CDLE) but the response to treatment is considerably variable between patients and is also unpredictable. The reason for this might relate to differences in metabolism of the drug which is extensively acetylated by the polymorphic enzyme N-acetyltransferase 2 (NAT2). To test this possibility, the N-acetylation phenotype of eleven patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Arylamine N-Acetyltransferase
Share to NAT2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 9170150
DOI: 10.1097/00008571-199704000-00006

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus.PMID 9170150Read ↗

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis.Semantic proximity Read ↗

Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.Semantic proximity Read ↗

Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.Semantic proximity Read ↗

Arylamine N-acetyltransferase polymorphisms in Han Chinese patients with ankylosing spondylitis and their correlation to the adverse drug reactions to sulfasalazine.Semantic proximity Read ↗

Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test.Semantic proximity Read ↗

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.Semantic proximity Read ↗

Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics.Semantic proximity Read ↗

Increased genotype frequency of N-acetyltransferase 2 slow acetylation in patients with rheumatoid arthritis.Semantic proximity Read ↗

N-acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism.Semantic proximity Read ↗

N-acetyltransferase 2 acetylation polymorphism: prevalence of slow acetylators does not differ between atopic dermatitis patients and healthy subjects.Semantic proximity Read ↗

N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.Semantic proximity Read ↗

N-acetylation phenotyping with sulfamethazine in an Iranian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.